A Randomized, Open-Label, Non-inferiority Clinical Trial Assessing 7 Versus 14 Days of Antimicrobial Therapy for Severe Multidrug-Resistant Gram-Negative Bacterial Infections: The OPTIMISE Trial Protocol.

Authors: Arns, Beatriz, Horvath, Jaqueline Driemeyer C., Rech, Gabriela Soares, Sesin, Guilhermo Prates, Agani, Crepin Aziz Jose Oluwafoumi, da Rosa, Bruna Silveira, dos Santos, Tiago Marcon, Brochier, Liliane Spencer Bittencourt, Cavalcanti, Alexandre Biasi, Tomazini, Bruno Martins, Pereira, Adriano Jose, Veiga, Viviane Cordeiro, Nascimento, Giovana Marssola, Kalil, Andre C., Zavascki, Alexandre P.

Source: Infectious Diseases & Therapy; Jan2024, Vol. 13 Issue 1, p237-250, 14p

A Randomized, Open-Label, Non-inferiority Clinical Trial Assessing 7 Versus 14 Days of Antimicrobial Therapy for Severe Multidrug-Resistant Gram-Negative Bacterial Infections: The OPTIMISE Trial Protocol

Authors: Arns, Beatriz, Horvath, Jaqueline Driemeyer C., Rech, Gabriela Soares, Sesin, Guilhermo Prates, Agani, Crepin Aziz Jose Oluwafoumi, da Rosa, Bruna Silveira, dos Santos, Tiago Marcon, Brochier, Liliane Spencer Bittencourt, Cavalcanti, Alexandre Biasi, Tomazini, Bruno Martins, Pereira, Adriano Jose, Veiga, Viviane Cordeiro, Nascimento, Giovana Marssola, Kalil, Andre C., Zavascki, Alexandre P.

Source: Infectious Diseases and Therapy; 20230101, Issue: Preprints p1-14, 14p